Ambarella Beat Expectations but Wall Street Hit the Brakes — Can the Edge AI Chipmaker Outrun Its Memory Headwinds?

Shares of Ambarella sank 7.4% to $58.69 on September 4, extending a punishing five-day slide from $70.63, after two analyst firms slashed their outlooks the morning after what was, on paper, a solid quarterly report. The selloff crystallizes a growing worry: even as Ambarella's AI chip business grows, forces outside its control may cap how fast that growth can translate into profits.

• A Beat That Wasn't Good Enough — Ambarella posted Q2 fiscal 2027 revenue of $108.1 million, up 13.2% year-over-year and above the midpoint of guidance.

Non-GAAP earnings came in at $0.18 per share, with gross margin of 59.3%, below the midpoint due to rising supply chain costs. The numbers cleared the bar, yet investors were left "unsatisfied" because the forward picture is cloudier than the rearview mirror.

• Memory Prices Threaten to Choke Customer Orders — Ambarella doesn't buy or resell memory chips, so rising DRAM prices don't directly cut its margins. But its customers do buy memory, and that's the problem. CEO Fermi Wang explained the real risk: because customers must raise their own prices, "that will reduce the total volume they can sell and therefore reduce the total ordering to us."

Management acknowledged "the outlook for Q4 remains uncertain due to memory constraints." That single admission spooked analysts.

• Two Downgrades, One Message: Wait and See — Craig-Hallum downgraded Ambarella to Hold, citing "DRAM pricing risks and limited visibility on AI growth drivers," and sliced its price target from $95 to $70. Roth Capital cut its target to $65 from $90 while keeping a Neutral rating. With the stock now trading below both new targets, the market is pricing in more pain than even the bears forecast.

• The Long Game Still Has Promise — If Demand Holds — Ambarella expanded its five-year addressable market estimate to $22.9 billion by fiscal 2032, representing a 20% compound annual growth rate.

New partnerships with Capgemini and Macnica could each generate up to $500 million in added revenue over seven years. But with free cash flow negative at $7.1 million and inventory days climbing to 157 , Ambarella must prove near-term execution before long-term opportunity matters to shareholders.

The stock has now shed 17% in a week. Investors aren't doubting the AI story — they're questioning the timetable.